Zobrazeno 1 - 10
of 3 645
pro vyhledávání: '"Ramsden D"'
Autor:
Reddy MB; Clinical Pharmacology, Oncology, Pfizer Inc., Boulder, Colorado, USA., Cabalu TD; DMPK, Pharmacokinetics, Dynamics, Metabolism, and Bioanalytics, Merck & Co., Inc., Rahway, New Jersey, USA., de Zwart L; DMPK, Janssen Pharmaceutica NV, A Johnson & Johnson Company, Beerse, Belgium., Ramsden D; DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts, USA., Dowty ME; Pharmacokinetics Dynamics and Metabolism, Pfizer Inc, Cambridge, Massachusetts, USA., Taskar KS; DMPK, Pre-Clinical Sciences, Research Technologies, GSK, Stevenage, UK., Badée J; PK Sciences, Biomedical Research, Novartis, Basel, Switzerland., Bolleddula J; Quantitative Pharmacology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA., Boulu L; Modeling and Simulation, Translational Medicine and Early Development, Sanofi, Montpellier, France., Fu Q; Modeling and Simulation, Vertex Pharmaceuticals, Boston, Massachusetts, USA., Kotsuma M; Quantitative Clinical Pharmacology, Daiichi Sankyo Co., Ltd., Tokyo, Japan., Leblanc AF; Quantitative, Translational & ADME Sciences, Development Science, AbbVie, North Chicago, Illinois, USA., Lewis G; DMPK, Pre-Clinical Sciences, Research Technologies, GSK, Stevenage, UK., Liang G; DMPK, Vertex Pharmaceuticals, Boston, Massachusetts, USA., Parrott N; Pharmaceutical Sciences, Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland., Pilla Reddy V; Global PKPD/Pharmacometrics, Eli Lilly and Company, Bracknell, UK and Indianapolis, Indiana, USA., Prakash C; DMPK and Clinical Pharmacology, Agios, Cambridge, Massachusetts, USA., Shah K; Quantitative Clinical Pharmacology, Takeda Pharmaceuticals International Inc., Cambridge, Massachusetts, USA., Umehara K; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland., Mukherjee D; Quantitative Clinical Pharmacology, Daiichi-Sankyo Inc., Basking Ridge, New Jersey, USA., Rehmel J; Global PKPD/Pharmacometrics, Eli Lilly and Company, Bracknell, UK and Indianapolis, Indiana, USA., Hariparsad N; DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts, USA.
Publikováno v:
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2024 Oct 18. Date of Electronic Publication: 2024 Oct 18.
Autor:
Tomlinson L; Global Pathology, Pfizer Inc., Cambridge, MA, 02140, USA., Ramsden D; DMPK Oncology, AstraZeneca, Boston, MA, 02451, USA., Leite SB; European Commission Joint Research Centre, Ispra, 21027, Italy., Beken S; Federal Agency for Medicines and Health Products, Brussels, 1210, Belgium., Bonzo JA; Center for Drug Evaluation and Research, Office of New Drugs, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA., Brown P; Center for Drug Evaluation and Research, Office of New Drugs, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA., Candarlioglu PL; Complex In Vitro Models, GSK, Stevenage, SG1 2NY, UK., Chan TS; Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 06877, USA., Chen E; DMPK, Genentech, South San Francisco, CA, 94080, USA., Choi CK; Preclinical Safety, Biogen, Cambridge, MA, 02142, USA., David R; Clinical Pharmacology & Safety Sciences, AstraZeneca, Cambridge, CB2 0AA, UK., Delrue N; Organisation for Economic Co-operation and Development, Paris, 75016, France., Devine PJ; Discovery Toxicology, Bristol Myers Squibb, San Diego, CA, 09130, USA., Ford K; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA., Garcia MI; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA., Gosset JR; DMPK, Pfizer Inc., Cambridge, MA, 02139, USA., Hewitt P; Chemical and Preclinical Safety, Merck Healthcare KGaA, 64293, Darmstadt, Germany., Homan K; Complex in Vitro Systems Group, Genentech, South San Francisco, CA, 94080, USA., Irrechukwu O; Preclinical Sciences and Translational Safety, Johnson and Johnson Innovation Medicine, Spring House, PA, 19002, USA., Kopec AK; Drug Safety Research & Development, Pfizer Inc., Groton, CT, 06340, USA., Liras JL; Pharmacokinetics, Dynamics & Metabolism-Medicine Design, Pfizer, Cambridge, MA, 02139, USA., Mandlekar S; Clinical Pharmacology, Genentech, South San Francisco, CA, 94080, USA., Raczynski A; Preclinical Safety Assessment, Vertex Pharmaceuticals Inc., Boston, MA, 02210, USA., Sadrieh N; Center for Drug Evaluation and Research, Office of New Drugs, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA., Sakatis MZ; Non-Clinical Safety, In Vitro/In Vivo Translation, GSK R&D, Ware, SG12 9TJ, UK., Siegel J; Center for Drug Evaluation and Research, Office of New Drugs, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA., Sung K; Center for Biologics Evaluation and Research, Office of Cellular Therapy and Human Tissue, Cellular and Tissue Therapy Branch, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA., Sunyovszki I; Translational Cellular Sciences, Biogen, Cambridge, MA, 02142, USA., Van Vleet TR; AbbVie, Inc., North Chicago, IL, 60064, USA., Ekert JE; UCB Pharma, Cambridge, MA, 02140, USA., Hardwick RN; Discovery Toxicology, Bristol Myers Squibb, San Diego, CA, 09130, USA.
Publikováno v:
Advanced biology [Adv Biol (Weinh)] 2024 Aug; Vol. 8 (8), pp. e2300131. Date of Electronic Publication: 2023 Oct 09.
Autor:
Chothe PP; Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Waltham, MA, USA., Argikar UA; Non-clinical Development, Bill and Melinda Gates Medical Research Institute, Cambridge, MA, USA., Mitra P; Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA., Nakakariya M; Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda irinote Pharmaceutical Company Limited, Fujisawa, Japan., Ramsden D; Preclinical Development, Korro Bio, Inc. One Kendall Square, Cambridge, MA, USA., Rotter CJ; Global Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc. (TDCA), San Diego, CA, USA., Sandoval P; Global Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Tohyama K; Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda irinote Pharmaceutical Company Limited, Fujisawa, Japan.
Publikováno v:
Drug metabolism reviews [Drug Metab Rev] 2024 Nov; Vol. 56 (4), pp. 318-348. Date of Electronic Publication: 2024 Sep 11.
Autor:
Aluri KC; Drug Metabolism and Pharmacokinetics, Oncology R&D, AstraZeneca, 35 Gatehouse Park Drive, Waltham, MA 02451, United States., Sigfridsson K; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, 431 83 Mölndal, Sweden., Xue A; Animal Sciences and Technologies, Clinical Pharmacology and Safety Sciences, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, United States., Ramsden D; Drug Metabolism and Pharmacokinetics, Oncology R&D, AstraZeneca, 35 Gatehouse Park Drive, Waltham, MA 02451, United States.
Publikováno v:
The Journal of pharmacy and pharmacology [J Pharm Pharmacol] 2024 Sep 14. Date of Electronic Publication: 2024 Sep 14.
Autor:
Gosselin E; DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, MA, USA., Pop-Damkov P; DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, MA, USA., Xue A; Animal Sciences & Technology, Clinical Pharmacology and Safety Sciences, Biopharmaceutical R&D, AstraZeneca, Waltham, MA, USA., Markandu R; Early Oncology Clinical, Oncology R&D, AstraZeneca, Cambridge, UK., Mlynarski S; Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, MA, USA., Finlay R; Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Schuller A; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca,Waltham, MA, USA., Ramsden D; DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, MA, USA., Gangl ET; Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, Waltham, USA.
Publikováno v:
Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2024 Aug 15; Vol. 246, pp. 116210. Date of Electronic Publication: 2024 May 08.
Autor:
Yu M; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Qin J; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Liu X; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Ramsden D; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Williams B; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Zlatev I; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Guenther D; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Matsuda S; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Tymon R; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Darcy J; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Wong C; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Tsung J; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Zawaneh P; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Chong S; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Theile CS; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Taneja N; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Rogers A; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Liu J; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Castellanos-Rizaldos E; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Bond S; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., So K; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Denoncourt J; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Castoreno A; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Manoharan M; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Wu JT; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Fitzgerald K; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Maier MA; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Jadhav V; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Nair JK; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA.
Publikováno v:
Nucleic acids research [Nucleic Acids Res] 2024 Jun 10; Vol. 52 (10), pp. 5423-5437.
Autor:
Vasalou C; Clinical Pharmacology & Safety Sciences, Waltham, Massachusetts, USA., Proia TA; Translational Medicine, Waltham, Massachusetts, USA., Kazlauskas L; AstraZeneca Research & Development, Waltham, Massachusetts, USA., Przybyla A; AstraZeneca Research & Development, Waltham, Massachusetts, USA., Sung M; AstraZeneca Research & Development, Waltham, Massachusetts, USA., Mamidi S; AstraZeneca Research & Development, Cambridge, UK., Maratea K; Clinical Pharmacology & Safety Sciences, Waltham, Massachusetts, USA., Griffin M; Clinical Pharmacology & Safety Sciences, Waltham, Massachusetts, USA., Sargeant R; Clinical Pharmacology & Safety Sciences, Cambridge, UK., Urosevic J; AstraZeneca Research & Development, Cambridge, UK., Rosenbaum AI; Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, South San Francisco, California, USA., Yuan J; Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, South San Francisco, California, USA., Aluri KC; AstraZeneca Research & Development, Waltham, Massachusetts, USA., Ramsden D; AstraZeneca Research & Development, Waltham, Massachusetts, USA., Hariparsad N; AstraZeneca Research & Development, Waltham, Massachusetts, USA., Jones RDO; AstraZeneca Research & Development, Cambridge, UK., Mettetal JT; AstraZeneca Research & Development, Waltham, Massachusetts, USA.
Publikováno v:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Jun; Vol. 13 (6), pp. 994-1005. Date of Electronic Publication: 2024 Mar 26.
Autor:
Aluri KC; Novo Nordisk, Lexington, Massachusetts, USA., Slavsky M; AstraZeneca, Waltham, Massachusetts, USA., Tan Y; AstraZeneca, Waltham, Massachusetts, USA., Whitcher-Johnstone A; AstraZeneca, Waltham, Massachusetts, USA., Zhang Z; AstraZeneca, Waltham, Massachusetts, USA., Hariparsad N; AstraZeneca, Waltham, Massachusetts, USA., Ramsden D; Korro Bio, Cambridge, Massachusetts, USA.
Publikováno v:
Clinical and translational science [Clin Transl Sci] 2024 Mar; Vol. 17 (3), pp. e13746.
Autor:
Chothe PP; Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Waltham, Massachusetts (P.P.C., D.R.); Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland (V.A.); Department of Pharmaceutical Sciences, Washington State University, Spokane, Washington (B.P.); and Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, R&D, Stevenage, United Kingdom (K.T.) paresh.chothe@astrazeneca.com., Arya V; Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Waltham, Massachusetts (P.P.C., D.R.); Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland (V.A.); Department of Pharmaceutical Sciences, Washington State University, Spokane, Washington (B.P.); and Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, R&D, Stevenage, United Kingdom (K.T.)., Prasad B; Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Waltham, Massachusetts (P.P.C., D.R.); Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland (V.A.); Department of Pharmaceutical Sciences, Washington State University, Spokane, Washington (B.P.); and Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, R&D, Stevenage, United Kingdom (K.T.)., Ramsden D; Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Waltham, Massachusetts (P.P.C., D.R.); Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland (V.A.); Department of Pharmaceutical Sciences, Washington State University, Spokane, Washington (B.P.); and Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, R&D, Stevenage, United Kingdom (K.T.)., Taskar K; Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Waltham, Massachusetts (P.P.C., D.R.); Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland (V.A.); Department of Pharmaceutical Sciences, Washington State University, Spokane, Washington (B.P.); and Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, R&D, Stevenage, United Kingdom (K.T.).
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2023 Dec; Vol. 51 (12), pp. 1547-1550. Date of Electronic Publication: 2023 Sep 29.
Autor:
Chothe PP; Department of Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Waltham, MA, USA., Mitra P; Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA., Nakakariya M; Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Fujisawa, Japan., Ramsden D; Department of Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Waltham, MA, USA., Rotter CJ; Global Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc. (TDCA), San Diego, CA, USA., Sandoval P; Global Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Tohyama K; Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
Publikováno v:
Drug metabolism reviews [Drug Metab Rev] 2023 Nov; Vol. 55 (4), pp. 343-370. Date of Electronic Publication: 2023 Sep 06.